| Literature DB >> 34893069 |
Qiyu Yang1, Lixia Zhu1, Meng Wang1, Bo Huang1, Zhou Li1, Juan Hu1, Qingsong Xi2, Jing Liu3, Lei Jin4.
Abstract
BACKGROUND: To improve the developmental competence of in vitro cultured oocytes, extensive literature focused on maturation rate improvement with different additives in culture medium, while studies investigating the maturation dynamics of oocytes during in vitro maturation (IVM) and the influencing factors on oocyte viability are scarce.Entities:
Keywords: Developmental competence; In vitro maturation; Oocyte maturation dynamics; Progesterone; Time-lapse monitoring
Mesh:
Year: 2021 PMID: 34893069 PMCID: PMC8662918 DOI: 10.1186/s12958-021-00868-0
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Fig. 1The overall flowchart of data collection and analyses. Baseline characteristics, morphological parameters, and maturation dynamics of the oocytes undergoing R-IVM were comprehensively documented and their effects on 24-h maturation rate, normal fertilization rate, and high-quality embryo formation rate were assessed
Baseline characteristics of fifty-nine involved female patients
| Patient Characteristics ( | Values |
|---|---|
| Age, years | 31.8 ± 0.6 |
| BMI, kg/m2 | 21.1 ± 0.3 |
| Infertility type, n (%) | |
| Primary | 41 (69.5%) |
| Secondary | 18 (30.5%) |
| Infertility duration, years | 2.3 (2–6) |
| Basal serum FSH level, mIU/ml | 6.8 (5.9–7.8) |
| Antral follicle count | 14.9 ± 0.9 |
| Serum AMH level, ng/ml | 4.7 (2.9–8.3) |
| Ovarian stimulation protocol, n (%) | |
| GnRH agonist protocol | 32 (54.2%) |
| GnRH antagonist protocol | 27 (45.8%) |
| Ovarian response | |
| Serum E2 level on hCG trigger day, pg/ml | 2567.0 (1541.5–4253.0) |
| Serum P level on hCG trigger day, ng/ml | 0.9 (0.6–1.1) |
| Oocytes obtained, n | 14 (8.5–21.0) |
| Mature oocytes obtained, n | 10 (5–17) |
| Maturation rate at retrieval | 68.4% |
| Normal fertilization rate | 73.4% |
| Available embryo formation rate | 68.0% |
| OHSS rate | 8.5% |
BMI body mass index, FSH follicle stimulating hormone, AMH anti-Müllerian hormone; E2 estradiol, P progesterone, OHSS Ovarian hyperstimulation syndrome
Fig. 2The time distribution of each stage in all oocytes resuming meiosis. The duration of GV-MI (the red area) varied between 0.3 h and 44 h, with a dispersion coefficient of 0.95. The duration of MI-MII (the blue area) ranged from 8.6 h to 21.5 h, with a dispersion coefficient of 0.13. The duration of maturation (the green area) ranged from 9.1 h to 64 h, with a dispersion coefficient of 0.20. The numbers marked on the image were the median duration of GVBD, MI-MII, and maturation
Analysis of factors affecting 24-h maturation rate of 157 GV oocytes during R-IVM
| Maturation rate in 24 h, % | Chi square | OR | 95% CI | ||
|---|---|---|---|---|---|
| Age of patients involved, years | 0.006 | 0.936 | 0.974 | 0.517–1.837 | |
| < 33 ( | 57.0 | ||||
| ≥ 33 ( | 56.3 | ||||
| FSH, mIU/ml | 0.222 | 0.638 | 1.174 | 0.602–2.288 | |
| < 7 ( | 55.3 | ||||
| ≥ 7 ( | 59.3 | ||||
| AMH, ng/ml | 0.044 | 0.835 | 1.080 | 0.524–2.226 | |
| < 4 ( | 55.0 | ||||
| ≥ 4 ( | 56.9 | ||||
| Ovarian stimulation protocol | 0.037 | 0.848 | 1.064 | 0.561–2.019 | |
| GnRH agonist protocol ( | 56.0 | ||||
| GnRH antagonist protocol ( | 57.6 | ||||
| E2 on hCG day, pg/ml | 0.330 | 0.566 | 0.831 | 0.442–1.563 | |
| < 3000 ( | 59.0 | ||||
| ≥ 3000 ( | 54.4 | ||||
| P on hCG day, ng/ml | 0.087 | 0.786 | 1.100 | 0.585–2.070 | |
| < 1 ( | 55.6 | ||||
| ≥ 1 ( | 57.9 | ||||
| GV diameter, μm | 0.006 | 0.938 | 0.973 | 0.492–1.925 | |
| < 30 ( | 57.1 | ||||
| ≥ 30 ( | 56.5 | ||||
| Oocyte diameter, μm | 0.011 | 0.917 | 1.036 | 0.537–1.996 | |
| < 110 ( | 56.1 | ||||
| ≥ 110 ( | 57.0 |
FSH follicle stimulating hormone, AMH anti-Müllerian hormone, E2 estradiol, P progesterone, GV germinal vesicle
Analysis of factors influencing normal fertilization rate of 104 matured oocytes following ICSI
| Normal fertilization rate, % | Chi square | OR | 95% CI | ||
|---|---|---|---|---|---|
| Patient age, years | 2.239 | 0.135 | 0.548 | 0.249–1.208 | |
| < 33 ( | 50.0 | ||||
| ≥ 33 ( | 35.4 | ||||
| FSH, mIU/ml | 0.351 | 0.553 | 0.783 | 0.348–1.761 | |
| < 7 ( | 45.5 | ||||
| ≥ 7 ( | 39.5 | ||||
| AMH, ng/ml | 0.027 | 0.087 | 1.078 | 0.439–2.649 | |
| < 4 ( | 42.3 | ||||
| ≥ 4 ( | 44.2 | ||||
| E2 on hCG day, pg/ml | 1.777 | 0.182 | 1.700 | 0.777–3.718 | |
| < 3000 ( | 37.0 | ||||
| ≥ 3000 ( | 50.0 | ||||
| P on hCG day, ng/ml | 0.001 | 0.979 | 0.990 | 0.455–2.150 | |
| < 1 ( | 43.4 | ||||
| ≥ 1 ( | 43.1 | ||||
| GV diameter, μm | 1.829 | 0.176 | 0.561 | 0.242–1.301 | |
| < 30 ( | 53.1 | ||||
| ≥ 30 ( | 38.9 | ||||
| Oocyte diameter, μm | 1.105 | 0.293 | 0.650 | 0.291–1.454 | |
| < 110 ( | 50.0 | ||||
| ≥ 110 ( | 39.4 | ||||
| GV-MI, h | 8.217 | 0.136 | 0.029–0.633 | ||
| < 8 ( | 49.4 | ||||
| ≥ 8 ( | 11.8 | ||||
| MI-MII, h | 0.863 | 0.353 | 0.690 | 0.315–1.512 | |
| < 16 ( | 47.4 | ||||
| ≥ 16 ( | 38.3 | ||||
| GV-MII, h | 6.399 | 0.165 | 0.035–0.772 | ||
| < 24 ( | 48.3 | ||||
| ≥ 24 ( | 13.3 | ||||
| MII-ICSI, h | 0.410 | 0.522 | 0.769 | 0.344–1.719 | |
| < 6 ( | 47.4 | ||||
| ≥ 6 ( | 40.9 |
FSH follicle stimulating hormone, AMH anti-Müllerian hormone, E2 estradiol, P progesterone, GV germinal vesicle
Analysis of factors influencing the high-quality embryo formation rate of 54 zygotes derived from oocytes matured within 24 h
| High-quality embryo formation rate, % | Chi square | OR | 95% CI | ||
|---|---|---|---|---|---|
| Patient age, years | 0.162 | 0.687 | 1.273 | 0.393–4.117 | |
| < 33 ( | 31.4 | ||||
| ≥ 33 ( | 36.8 | ||||
| FSH, mIU/ml | 1.015 | 0.314 | 1.818 | 0.565–5.854 | |
| < 7 ( | 28.6 | ||||
| ≥ 7 ( | 42.1 | ||||
| AMH, ng/ml | 3.726 | 0.071 | 0.258 | 0.062–1.078 | |
| < 4 ( | 60.0 | ||||
| ≥ 4 ( | 27.9 | ||||
| E2 on hCG day, pg/ml | 0.149 | 0.700 | 0.800 | 0.257–2.486 | |
| < 3000 ( | 36.0 | ||||
| ≥ 3000 ( | 31.6 | ||||
| P on hCG day, ng/ml | 4.506 | 0.283 | 0.086–0.932 | ||
| < 1 ( | 48.0 | ||||
| ≥ 1 ( | 20.7 | ||||
| GV diameter, μm | 3.375 | 0.066 | 0.333 | 0.101–1.099 | |
| < 30 ( | 50.0 | ||||
| ≥ 30 ( | 25.0 | ||||
| Oocyte diameter, μm | 0.375 | 0.540 | 0.691 | 0.212–2.258 | |
| < 110 ( | 38.9 | ||||
| ≥ 110 ( | 30.6 | ||||
| GV-MI, h | 4.441 | 0.196 | 0.039–0.988 | ||
| < 4.5 ( | 42.1 | ||||
| ≥ 4.5 ( | 12.5 | ||||
| MI-MII, h | 0.993 | 0.319 | 0.538 | 0.158–1.835 | |
| < 16 ( | 38.2 | ||||
| ≥ 16 ( | 25.0 | ||||
| GV-MII, h | 6.400 | 0.220 | 0.066–0.738 | ||
| < 19 ( | 52.2 | ||||
| ≥ 19 ( | 19.4 | ||||
| MII-ICSI, h | 1.403 | 0.236 | 2.080 | 0.612–7.067 | |
| < 6 ( | 23.8 | ||||
| ≥ 6 ( | 39.4 |
FSH follicle stimulating hormone, AMH anti-Müllerian hormone, E2,estradiol, P progesterone, GVs germinal vesicle